NCI

November 2, 2021

Shifts in neuroendocrine cancer clinical trial design

Clinical trials that focus on specific types of neuroendocrine neoplasms — heterogeneous tumors that can occur anywhere in the body — will be more likely to enhance drug development for these tumors, Vanderbilt physicians assert.

By Leigh MacMillan
November 1, 2021

Breast cancer survivors: eat nuts

Breast cancer survivors who reported eating nuts regularly had 50% reduced risk of breast cancer recurrence, metastasis or mortality, Vanderbilt epidemiologists found in Shanghai Breast Cancer Survival Study.

By Leigh MacMillan
October 28, 2021

Pancreatic beta-cell booster

Blocking inflammatory signaling improves beta-cell characteristics in a mouse model of type 2 diabetes and may provide added benefits to GLP-1R diabetes medications.

By Leigh MacMillan
October 14, 2021

Tea drinking and high blood pressure

Habitual tea drinking is associated with a slightly higher risk of hypertension in middle-aged and older Chinese adults, which warrants confirmation by long-term intervention studies, researchers say.

By Sarah E. Glass
Stomach
October 14, 2021

New marker for metaplasia

A protein that transports water, called aquaporin 5, is expressed by cells undergoing changes that may increase risk for gastric cancer development, Vanderbilt researchers discovered.

By Bill Snyder
September 21, 2021

The role of polarity in early cancer

Mutations in the protein epiregulin, an EGF receptor ligand, affect larger epithelial cell reorganization and may contribute to early cancer development, Vanderbilt researchers discovered.

By VUMC News and Communications
September 16, 2021

Structural variants in breast cancer risk genes

Vanderbilt epidemiologists conducted in-depth whole genome sequencing of breast cancer risk genes in Black women, who die at higher rates and have more aggressive disease, to discover mutations that may improve testing and treatment selection.
By Leigh MacMillan
September 2, 2021

Discovery offers insight for development of cancer therapies targeting mutant p53

Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.
By Bill Snyder
August 19, 2021

Expression atlas for cell regulators

Vanderbilt researchers report a comprehensive tissue-specific atlas of protein and mRNA expression for p63 and p73, members of the p53 family signaling network that is the most frequent target of mutations in human cancers.
By Leigh MacMillan
August 12, 2021

Study reveals missing link between high-fat diet, microbiota and heart disease

A high-fat diet disrupts the biology of the gut’s inner lining and its microbial communities — and promotes the production of a metabolite that may contribute to heart disease, according to a study published Aug. 13 in the journal Science.
By Leigh MacMillan
July 27, 2021

Prediction models for breast cancer

Vanderbilt researchers developed new prognostic models for breast cancer outcomes and found that adding postdiagnostic weight change as a factor improves the prediction.
By Leigh MacMillan
July 22, 2021

Researchers discover that protein switches functions to regulate DNA replication

Vanderbilt biochemists have discovered what the DNA damage response protein RADX does — and how it does it.
By Leigh MacMillan
May 6, 2021

Study finds that regulatory protein prevents signaling that triggers cell death

A protein implicated in neurodegenerative diseases including amyotrophic lateral sclerosis prevents the activation of an innate immune response that leads to cell death, Vanderbilt researchers have discovered.
By Leigh MacMillan
1 2 3 4 5 6 … 28